LivaNova (LIVN) Depreciation & Amortization (CF) (2015 - 2026)
LivaNova (LIVN) reported Depreciation & Amortization (CF) of $8.3 million for Q1 2026, up 29.3% on a YoY basis from $6.4 million in Q1 2025, and up 9.86% sequentially from $7.6 million in Q4 2025.
LivaNova (LIVN) Depreciation & Amortization (CF) (2015 - 2026) Analysis & Trends
LivaNova (LIVN) has 12 years of Depreciation & Amortization (CF) data on file, last reported at $8.3 million in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 29.3% year-over-year to $8.3 million; the trailing twelve-month figure through Mar 2026 stood at $30.4 million (up 57.72% YoY), and the FY2025 full-year result was $28.6 million, up 65.95% from the prior year.
- Depreciation & Amortization (CF) grew to $8.3 million in Q1 2026, from $7.6 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $8.3 million in Q1 2026 to a low of $4.3 million in Q4 2024.
- A 5-year average of $6.2 million and a median of $6.4 million in 2023 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) tumbled 32.97% in 2024 and surged 77.68% in 2025, its largest moves.
- Tracing LIVN's Depreciation & Amortization (CF) over 5 years: stood at $6.2 million in 2022, then climbed by 1.85% to $6.3 million in 2023, then plunged by 32.97% to $4.3 million in 2024, then surged by 77.68% to $7.6 million in 2025, then increased by 9.86% to $8.3 million in 2026.
- Business Quant data shows LIVN's Depreciation & Amortization (CF) at $8.3 million in Q1 2026, $7.6 million in Q4 2025, and $7.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 381.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 120.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 716.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 351.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 40.90 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 67.10 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 310.25 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 78.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | LivaNova | 4.30 Bn | 3.76 Bn | 243.75 Mn | 8.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.30 Mn |
| Mar 31, 2026 | 8.30 Mn |
| Dec 31, 2025 | 7.56 Mn |
| Dec 31, 2025 | 7.56 Mn |
| Sep 30, 2025 | 7.72 Mn |
| Sep 30, 2025 | 7.72 Mn |
| Jun 30, 2025 | 6.87 Mn |
| Jun 30, 2025 | 6.87 Mn |
| Mar 31, 2025 | 6.42 Mn |
| Mar 31, 2025 | 6.42 Mn |
| Dec 31, 2024 | 4.25 Mn |
| Dec 31, 2024 | 4.25 Mn |
| Sep 30, 2024 | 4.35 Mn |
| Sep 30, 2024 | 4.35 Mn |
| Jun 30, 2024 | 4.29 Mn |
| Jun 30, 2024 | 4.29 Mn |
| Mar 31, 2024 | 4.33 Mn |
| Mar 31, 2024 | 4.33 Mn |
| Dec 31, 2023 | 6.34 Mn |
| Dec 31, 2023 | 6.34 Mn |